Evercore ISI Senior Managing Director Umer Raffat is one of the most well-respected biotech and pharma sell-side analysts on Wall Street, having landed a number-one spot on Institutional Investor’s annual analyst rankings 19 times. Clients and industry insiders rely on his prolific insights on hot topics like the prospects of GLP-1 pills for weight loss as well as his keen eye for news — as when, earlier this year, Raffat spotted Roche’s accidental posting of data from a clinical trial testing its anti-TIGIT antibody that it had not yet made public.
Industry
Location
-
New York, N.Y.
